Pfizer, GSK collaborate on PCMM prototype for OSD
Pfizer’s current PCMM prototype is an autonomous and transportable pod that may be quickly shipped from location to location and readily brought online to create a fully functional
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Utibron Neohaler (indacaterol/glycopyrrolate), which is expected to be available in the first quarter of next year, can be used for the long-term maintenance treatment of airflow obstruction in
The companies will use CEVEC’s CAPGo technology which is optimal for the production of these otherwise difficult to produce recombinant glycoproteins. Financial details of this agreement were not